Giuseppe Pizzorno, PhD, PharmD, has been named professor and associate dean of Research for the University of Tennessee Health Science Center (UTHSC) College of Medicine, Chattanooga campus and the first Chief Research Officer for Erlanger Health System.
“We were very fortunate to be able to identify and recruit Dr. Giuseppe Pizzorno to serve in dual roles,” said R. Bruce Shack, MD, dean of the College of Medicine in Chattanooga. “He brings with him an enormous amount of experience and expertise in study design and implementation. He will enable our campus to move to the next level as a provider of excellence in clinical research. Under Dr. Pizzorno’s leadership, we also plan to increase our collaboration with basic science researchers at the University of Tennessee at Chattanooga. We welcome him warmly to our team.”
Before joining UTHSC, Dr. Pizzorno was the founder, deputy director and head of Research for the Nevada Cancer Institute in Las Vegas. He was also the director of clinical pharmacology for the Yale Cancer Center and research director of the Yale Pediatric Pharmacology Research Unit at Yale University School of Medicine, in New Haven, Connecticut.
“As an academic medical center affiliated with the University of Tennessee College of Medicine, Erlanger Health System is proud to partner with medical experts who make it their mission to not only teach future professionals, but to also improve the health care in our region,” said William Jackson, MD, MBA, Erlanger Health System’s executive vice president and chief medical officer. “As a leader in providing world-class care, we look forward to working with Dr. Pizzorno, advancing our capabilities in medical research and offering the latest treatment protocols to our patients.”
Dr. Pizzorno received his Doctor of Pharmaceutical Chemistry and Technology and Doctor of Pharmacy degrees from the University of Genoa, Italy, where he graduated summa cum laude.
Dr. Pizzorno’s area of expertise is in clinical and preclinical pharmacology, experimental therapeutics, translational research, and clinical research as they relate to cancer. He is also an accomplished researcher and scholar. An active member of the American Association for Cancer Research, Dr. Pizzorno has reviewed material for the National Cancer Institute, National Institute of Child Health and Human Development, Department of Defense, American Cancer Society, the Union for International Cancer Control, the Journal of Pharmacology and Experimental Therapeutics, Cancer Research, Molecular Pharmacology and Pharmacology and Therapeutics, the Journal of Cancer, and more.
He has written or co-authored more than 100 scholarly articles during his career.